Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models

Acta Pharmacologica Sinica

Volumn 32, Issue 12, 2011, Pages 1433-1445

  Wang, Zhi Fei ^a   Fessler, Emily Bame ^a   Chuang, De Maw ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

angiogenesis; apoptosis; brain ischemia; glycogen synthase kinase 3; histone deacetylase; lamotrigine; lithium; neurogenesis; stroke; valproate

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GLYCOGEN SYNTHASE KINASE 3; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 6; LAMOTRIGINE; LITHIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN BCL 2; PROTEIN BCL XL; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; VALPROIC ACID; VASCULOTROPIN; VOLTAGE GATED SODIUM CHANNEL;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOPHAGY; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CALCIUM TRANSPORT; CELL MIGRATION; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; STEM CELL TRANSPLANTATION; UPREGULATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DISEASE MODELS, ANIMAL; HUMANS; LITHIUM COMPOUNDS; STROKE; TRIAZINES; VALPROIC ACID;

EID: 82955187985     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.140     Document Type: Review

References (133)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011; 123: e18-e209.
2. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-7.
3. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40: 2945-8.
4. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001; 56: 1015-20. (Pubitemid 32336306)
5. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008; 39: 924-8. (Pubitemid 351619542)
6. Bearden CE, Woogen M, Glahn DC. Neurocognitive and neuroimaging predictors of clinical outcome in bipolar disorder. Curr Psychiatry Rep 2010; 12: 499-504.
7. Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 2004; 16: 83-90.
8. Chuang DM. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann N Y Acad Sci 2005; 1053: 195-204.
9. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001; 7: 541-7. (Pubitemid 32448319)
10. Chuang DM, Manji HK. In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol Psychiatry 2007; 62: 4-6. (Pubitemid 46898231)
11. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter. Lancet 2000; 356: 1241-2.
12. Atmaca M, Ozdemir H, Cetinkaya S, Parmaksiz S, Belli H, Poyraz AK, et al. Cingulate gyrus volumetry in drug free bipolar patients and patients treated with valproate or valproate and quetiapine. J Psychiatr Res 2007; 41: 821-7. (Pubitemid 46693892)
13. Chiu CT, Chuang DM. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 2010; 128: 281-304.
14. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 2009; 32: 591-601.
15. Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. Voltagegated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 2010; 9: 413-24.
16. Deb P, Sharma S, Hassan KM. Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiology 2010; 17: 197-218.
17. Allen CL, Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke 2009; 4: 461-70.
18. Ito U, Ohno K, Nakamura R, Suganuma F, Inaba Y. Brain edema during ischemia and after restoration of blood flow. Measurement of water, sodium, potassium content and plasma protein permeability. Stroke 1979; 10: 542-7. (Pubitemid 9256246)
19. Iadecola C, Alexander M. Cerebral ischemia and inflammation. Curr Opin Neurol 2001; 14: 89-94. (Pubitemid 32116263)
20. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2007; 184: 53-68. (Pubitemid 46365991)
21. Danton GH, Dietrich WD. Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol 2003; 62: 127-36. (Pubitemid 36176947)
22. Garcia JH, Liu KF, Yoshida Y, Lian J, Chen S, del Zoppo GJ. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J Pathol 1994; 144: 188-99. (Pubitemid 24158372)
23. Schilling M, Besselmann M, Leonhard C, Mueller M, Ringelstein EB, Kiefer R. Microglial activation precedes and predominates over macrophage infiltration in transient focal cerebral ischemia: a study in green fluorescent protein transgenic bone marrow chimeric mice. Exp Neurol 2003; 183: 25-33. (Pubitemid 37075853)
24. Zhang Z, Chopp M, Powers C. Temporal profile of microglial response following transient (2 h) middle cerebral artery occlusion. Brain Res 1997; 744: 189-98. (Pubitemid 27032335)
25. Dong Y, Benveniste EN. Immune function of astrocytes. Glia 2001; 36: 180-90. (Pubitemid 33055906)
26. Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis 2008; 32: 200-19.
27. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck MP, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007; 6: 650-61. (Pubitemid 47202487)
28. Rosell A, Lo EH. Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 2008; 8: 82-9.
29. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 1996; 16: 360-6. (Pubitemid 26125324)
30. Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M, Chan PH. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 1999; 842: 92-100. (Pubitemid 29447856)
31. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999; 19: 624-33. (Pubitemid 30161214)
32. Park KP, Rosell A, Foerch C, Xing C, Kim WJ, Lee S, et al. Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Stroke 2009; 40: 2836-42.
33. Barr TL, Latour LL, Lee KY, Schaewe TJ, Luby M, Chang GS, et al. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke 2010; 41: e123-8.
34. Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH, Montaner J. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008; 39: 1121-6. (Pubitemid 351440679)
35. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21: 7724-32. (Pubitemid 32904971)
36. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007; 27: 697-709. (Pubitemid 46474608)
37. Lo EH. A new penumbra: transitioning from injury into repair after stroke. Nat Med 2008; 14: 497-500. (Pubitemid 351655209)
38. Lok J, Gupta P, Guo S, Kim WJ, Whalen MJ, van Leyen K, et al. Cellcell signaling in the neurovascular unit. Neurochem Res 2007; 32: 2032-45.
39. Jin K, Sun Y, Xie L, Childs J, Mao XO, Greenberg DA. Post-ischemic administration of heparin-binding epidermal growth factor-like growth factor (HB-EGF) reduces infarct size and modifies neurogenesis after focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 2004; 24: 399-408. (Pubitemid 38452231)
40. Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003; 53: 743-51. (Pubitemid 36622511)
41. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004; 35: 1732-7. (Pubitemid 38823656)
42. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000; 106: 829-38.
43. Fagan SC, Hess DC, Hohnadel EJ, Pollock DM, Ergul A. Targets for vascular protection after acute ischemic stroke. Stroke 2004; 35: 2220-5. (Pubitemid 39129589)
44. Hansen TM, Moss AJ, Brindle NP. Vascular endothelial growth factor and angiopoietins in neurovascular regeneration and protection following stroke. Curr Neurovasc Res 2008; 5: 236-45.
45. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005; 169: 681-91.
46. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006; 12: 441-5.
47. Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 1998; 9: 2081-4. (Pubitemid 28300570)
48. Bian Q, Shi T, Chuang DM, Qian Y. Lithium reduces ischemiainduced hippocampal CA1 damage and behavioral deficits in gerbils. Brain Res 2007; 1184: 270-6. (Pubitemid 350160570)
49. Ren M, Senatorov VV, Chen RW, Chuang DM. Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci U S A 2003; 100: 6210-5.
50. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996; 93: 8455-9. (Pubitemid 26269579)
51. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-8. (Pubitemid 27050234)
52. Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003; 24: 441-3. (Pubitemid 37088166)
53. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 2001; 280: 720-5. (Pubitemid 32924489)
54. Chuang DM, Wang Z, Chiu CT. GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Front Mol Neurosci 2011; 4: 15.
55. Ozaki N, Chuang DM. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J Neurochem 1997; 69: 2336-44. (Pubitemid 27495418)
56. Chen RW, Qin ZH, Ren M, Kanai H, Chalecka-Franaszek E, Leeds P, et al. Regulation of c-Jun N-terminal kinase, p38 kinase and AP-1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection. J Neurochem 2003; 84: 566-75. (Pubitemid 36182255)
57. Nonaka S, Hough CJ, Chuang DM. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A 1998; 95: 2642-7. (Pubitemid 28145996)
58. Takagi N, Shinno K, Teves L, Bissoon N, Wallace MC, Gurd JW. Transient ischemia differentially increases tyrosine phosphorylation of NMDA receptor subunits 2A and 2B. J Neurochem 1997; 69: 1060-5. (Pubitemid 27364826)
59. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002; 80: 589-97. (Pubitemid 34809967)
60. Ma J, Zhang GY. Lithium reduced N-methyl-D-aspartate receptor subunit 2A tyrosine phosphorylation and its interactions with Src and Fyn mediated by PSD-95 in rat hippocampus following cerebral ischemia. Neurosci Lett 2003; 348: 185-9. (Pubitemid 36980663)
61. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/ threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 1999; 96: 8745-50. (Pubitemid 29354862)
62. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 2002; 43: 1173-9. (Pubitemid 36009371)
63. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-41. (Pubitemid 27456390)
64. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3K/Akt-dependent pathway. EMB J 1997; 16: 6151-61. (Pubitemid 27458335)
65. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999; 274: 6039-42.
66. Broughton BR, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral ischemia. Stroke 2009; 40: e331-9.
67. Mielke K, Herdegen T. JNK and p38 stresskinases-degenerative effectors of signal-transduction-cascades in the nervous system. Prog Neurobiol 2000; 61: 45-60. (Pubitemid 30100402)
68. Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 1996; 74: 589-607. (Pubitemid 26343761)
69. Xu J, Culman J, Blume A, Brecht S, Gohlke P. Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. Stroke 2003; 34: 1287-92. (Pubitemid 36547530)
70. Camins A, Crespo-Biel N, Junyent F, Verdaguer E, Canudas AM, Pallas M. Calpains as a target for therapy of neurodegenerative diseases: putative role of lithium. Curr Drug Metab 2009; 10: 433-47.
71. Li Q, Li H, Roughton K, Wang X, Kroemer G, Blomgren K, et al. Lithium reduces apoptosis and autophagy after neonatal hypoxiaischemia. Cell Death Dis 2010; 1: e56.
72. Bijur GN, Jope RS. Opposing actions of phosphatidylinositol 3-kinase and glycogen synthase kinase-3beta in the regulation of HSF-1 activity. J Neurochem 2000; 75: 2401-8.
73. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000; 290: 1717-21. (Pubitemid 32004796)
74. Wen YD, Sheng R, Zhang LS, Han R, Zhang X, Zhang XD, et al. Neuronal injury in rat model of permanent focal cerebral ischemia is associated with activation of autophagic and lysosomal pathways. Autophagy 2008; 4: 762-9.
75. Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 2005; 170: 1101-11. (Pubitemid 41362642)
76. Rubinsztein DC, DiFiglia M, Heintz N, Nixon RA, Qin ZH, Ravikumar B, et al. Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy 2005; 1: 11-22.
77. Li H, Li Q, Du X, Sun Y, Wang X, Kroemer G, et al. Lithium-mediated long-term neuroprotection in neonatal rat hypoxia-ischemia is associated with antiinflammatory effects and enhanced proliferation and survival of neural stem/progenitor cells. J Cereb Blood Flow Metab 2011; 31: 2106-15.
78. Beurel E, Jope RS. Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J Neuroinflammation 2009; 6: 9.
79. Kim YR, van Meer MP, Tejima E, Murata Y, Mandeville JB, Dai G, et al. Functional MRI of delayed chronic lithium treatment in rat focal cerebral ischemia. Stroke 2008; 39: 439-47. (Pubitemid 351619469)
80. Guo S, Arai K, Stins MF, Chuang DM, Lo EH. Lithium upregulates vascular endothelial growth factor in brain endothelial cells and astrocytes. Stroke 2009; 40: 652-5.
81. Boku S, Nakagawa S, Masuda T, Nishikawa H, Kato A, Toda H, et al. Effects of mood stabilizers on adult dentate gyrus-derived neural precursor cells. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 111-7.
82. Kim JS, Chang MY, Yu IT, Kim JH, Lee SH, Lee YS, et al. Lithium selectively increases neuronal differentiation of hippocampal neural progenitor cells both in vitro and in vivo. J Neurochem 2004; 89: 324-36. (Pubitemid 38495981)
83. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000; 75: 1729-34.
84. Yan XB, Hou HL, Wu LM, Liu J, Zhou JN. Lithium regulates hippocampal neurogenesis by ERK pathway and facilitates recovery of spatial learning and memory in rats after transient global cerebral ischemia. Neuropharmacology 2007; 53: 487-95. (Pubitemid 47284182)
85. Shioda N, Han F, Fukunaga K. Role of Akt and ERK signaling in the neurogenesis following brain ischemia. Int Rev Neurobiol 2009; 85: 375-87.
86. Yoshida S, Kirino T, Tamura A, Basugi N, Sano K. Lithium ion does not protect brain against transient ischemia in gerbils. Stroke 1991; 22: 84-9.
87. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 2004; 89: 1358-67. (Pubitemid 38802657)
88. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007; 321: 892-901. (Pubitemid 46762687)
89. Qian YR, Lee MJ, Hwang S, Kook JH, Kim JK, Bae CS. Neuroprotection by valproic Acid in mouse models of permanent and transient focal cerebral ischemia. Korean J Physiol Pharmacol 2010; 14: 435-40.
90. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969-78. (Pubitemid 34062289)
91. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-41.
92. Leng Y, Chuang DM. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 2006; 26: 7502-12. (Pubitemid 44315219)
93. Kanai H, Sawa A, Chen RW, Leeds P, Chuang DM. Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicityinduced GAPDH nuclear accumulation and apoptotic deh in neurons. Pharmacogenomics J 2004; 4: 336-44. (Pubitemid 39341573)
94. Shao L, Young LT, Wang JF. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 2005; 58: 879-84. (Pubitemid 41790716)
95. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 2008; 28: 2576-88. (Pubitemid 351348211)
96. Sinn DI, Kim SJ, Chu K, Jung KH, Lee ST, Song EC, et al. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol Dis 2007; 26: 464-72. (Pubitemid 46578295)
97. Peng GS, Li G, Tzeng NS, Chen PS, Chuang DM, Hsu YD, et al. Valproate pretreatment protects dopaminergic neurons from LPSinduced neurotoxicity in rat primary midbrain cultures: role of microgia. Brain Res Mol Brain Res 2005; 134: 162-9. (Pubitemid 40403648)
98. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006; 11: 1116-25. (Pubitemid 44867481)
99. Faraco G, Pancani T, Formentini L, Mascagni P, Fossati G, Leoni F, et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol 2006; 70: 1876-84. (Pubitemid 44771903)
100. Marinova Z, Ren M, Wendland JR, Leng Y, Liang MH, Yasuda S, et al. Valproic acid induces functional heat-shock protein 70 via class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem 2009; 111: 976-87.
101. Marinova Z, Leng Y, Leeds P, Chuang DM. Histone deacetylase inhibition alters histone methylation associated with heat shock protein 70 promoter modifications in astrocytes and neurons. Neuropharmacology 2011; 60: 1109-15.
102. Zheng Z, Kim JY, Ma H, Lee JE, Yenari MA. Anti-inflammatory effects of the 70 kDa heat shock protein in experimental stroke. J Cereb Blood Flow Metab 2008; 28: 53-63.
103. Wang Z, Leng Y, Tsai LK, Leeds P, Chuang DM. Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab 2011; 31: 52-7.
104. Hao Y, Creson T, Zhang L, Li P, Du F, Yuan P, et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 2004; 24: 6590-9. (Pubitemid 38971708)
105. Hsieh J, Nakashima K, Kuwabara T, Mejia E, Gage FH. Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc Natl Acad Sci U S A 2004; 101: 16659-64. (Pubitemid 39557769)
106. Kim HJ, Leeds P, Chuang DM. The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem 2009; 110: 1226-40.
107. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 2009; 14: 51-9.
108. Borlongan CV. Bone marrow stem cell mobilization in stroke: a 'bonehead' may be good after all! Leukemia 2011. doi: 10.1038/ leu.2011.167
109. Tsai LK, Leng Y, Wang Z, Leeds P, Chuang DM. The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms. Neuropsychopharmacology 2010; 35: 2225-37.
110. Tsai LK, Wang Z, Munasinghe J, Leng Y, Leeds P, Chuang DM. Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model. Stroke 2011; 42: 2932-9.
111. Smith SE, Meldrum BS. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke 1995; 26: 117-21; discussion 21-2.
112. Shuaib A, Mahmood RH, Wishart T, Kanthan R, Murabit MA, Ijaz S, et al. Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study. Brain Res 1995; 702: 199-206.
113. Wiard RP, Dickerson MC, Beek O, Norton R, Cooper BR. Neuroprotective properties of the novel antiepileptic lamotrigine in a gerbil model of global cerebral ischemia. Stroke 1995; 26: 466-72.
114. Seckin H, Yigitkanli K, Besalti O, Kosemehmetoglu K, Ozturk E, Simsek S, et al. Lamotrigine attenuates cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. Surg Neurol 2008; 70: 344-51; discussion 51.
115. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986; 27: 490-7.
116. Kuo CC, Lu L. Characterization of lamotrigine inhibition of Na+ channels in rat hippocampal neurones. Br J Pharmacol 1997; 121: 1231-8. (Pubitemid 27303595)
117. Bacher A, Zornow MH. Lamotrigine inhibits extracellular glutamate accumulation during transient global cerebral ischemia in rabbits. Anesthesiology 1997; 86: 459-63. (Pubitemid 27093390)
118. Kirino T. Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res 1982; 239: 57-69. (Pubitemid 12101768)
119. Fan Y, Deng P, Wang YC, Lu HC, Xu ZC, Schulz PE. Transient cerebral ischemia increases CA1 pyramidal neuron excitability. Exp Neurol 2008; 212: 415-21.
120. Papazisis G, Kallaras K, Kaiki-Astara A, Pourzitaki C, Tzachanis D, Dagklis T, et al. Neuroprotection by lamotrigine in a rat model of neonatal hypoxic-ischaemic encephalopathy. Int J Neuropsychopharmacol 2008; 11: 321-9. (Pubitemid 351482501)
121. Yi YH, Guo WC, Sun WW, Su T, Lin H, Chen SQ, et al. Neuroprotection of lamotrigine on hypoxic-ischemic brain damage in neonatal rats: Relations to administration time and doses. Biologics 2008; 2: 339-44.
122. Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord 2002; 4: 137-44. (Pubitemid 34411276)
123. Chang YC, Rapoport SI, Rao JS. Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex. Neurochem Res 2009; 34: 536-41.
124. Kondziella D, Strandberg J, Lindquist C, Asztely F. Lamotrigine increases the number of BrdU-labeled cells in the rat hippocampus. Neuroreport 2011; 22: 97-100.
125. Collino M, Thiemermann C, Mastrocola R, Gallicchio M, Benetti E, Miglio G, et al. Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. Shock 2008; 30: 299-307.
126. Kelly S, Zhao H, Hua Sun G, Cheng D, Qiao Y, Luo J, et al. Glycogen synthase kinase 3beta inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia. Exp Neurol 2004; 188: 378-86. (Pubitemid 38891598)
127. Koh SH, Yoo AR, Chang DI, Hwang SJ, Kim SH. Inhibition of GSK 3 reduces infarct volume and improves neurobehavioral functions. Biochem Biophys Res Commun 2008; 371: 894-9.
128. Valerio A, Bertolotti P, Delbarba A, Perego C, Dossena M, Ragni M, et al. Glycogen synthase kinase-3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production. J Neurochem 2011; 116: 1148-59.
129. Wang MJ, Huang HY, Chen WF, Chang HF, Kuo JS. Glycogen synthase kinase-3beta inactivation inhibits tumor necrosis factoralpha production in microglia by modulating nuclear factor kappaB and MLK3/JNK signaling cascades. J Neuroinflammation 2010; 7: 99.
130. Huang WC, Lin YS, Wang CY, Tsai CC, Tseng HC, Chen CL, et al. Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells. Immunology 2009; 128: e275-86.
131. Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y, et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 2009; 34: 1395-405.
132. Tan JR, Koo YX, Kaur P, Liu F, Armugam A, Wong PT, et al. microRNAs in stroke pathogenesis. Curr Mol Med 2011; 11: 76-92.
133. Jeyaseelan K, Lim KY, Armugam A. MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. Stroke 2008; 39: 959-66. (Pubitemid 351619577)